Combinations ; See Below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Mycobutin | Pfizer Global Pharmaceuticals | Laborex Kenya Eurapharma Ltd | 150mg | 30 | Tablet | per tablet | KES 2,905.00 |
| Rifabutin More info | |
|---|---|
| Mode Of Action | Inhibition of DNA-dependent RNA polymerase activity in susceptible bacterial cells. |
| Drug Indication | Pulmonary TB (with other drugs); prophylaxis of Mycobacteria avium complex infection in immunocompromised patients with low CD4 count; non-tuberculous mycobacterial infections (with other drugs). |
| Precautions | To be administered always with another tuberculostatic agent, pregnancy, impaired liver functions, undernourished patients, late pregnancy (can cause post-natal haemorrhage), immunologic reactions with intermittent therapy, discontinue immediately if signs of hepatocells are noted, porphyria |
| Contra-Indications | Jaundice, impaired liver functions, lactation and pregnancy, new born infants. |
| Side Effects | Elevated liver enzymes; jaundice; hepatitis (not common); nausea and vomiting; anemia; leucopenia; cytopenia; haemolysis (not common); hypersensitivity reactions; coneal opacities (with long term use); orange-red colouration of urine, saliva and skin; arthralgia and myalgia; flu-like syndrome. |
| Dosage | Pulmonary TB (with other drugs): 150-450mg OD for upto 6 months after culture negative. Prophylaxis of Mycobacteria avium complex infection in immunocompromised patients with low CD4 count: 300mg OD; non-tuberculous mycobacterial infections (with other drugs): 150-600mg OD for upto 6 months after culture negative. |
| Pregnancy Category Description | Manufacturer advises that the drug should be avoided in pregnany as there is no adequate information on safety of the drug in pregancy is available |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Anti-Tuberculous Drugs |